Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in EGFR-overexpressing Triple-Negative Breast Cancer
NCT00739063Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2008
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2008; status: terminated.
02
Drugs
erlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00739063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00739063.